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Abstract
Both the hypothalamus-pituitary-adrenal (HPA) axis and the extrahypothalamic brain stress system are key elements of the
neural circuitry that regulates the negative states during abstinence from chronic drug exposure. Orexins have recently
been hypothesized to modulate the extended amygdala and to contribute to the negative emotional state associated with
dependence. This study examined the impact of chronic morphine and withdrawal on the lateral hypothalamic (LH) orexin
A (OXA) gene expression and activity as well as OXA involvement in the brain stress response to morphine abstinence. Male
Wistar rats received chronic morphine followed by naloxone to precipitate withdrawal. The selective OX1R antagonist
SB334867 was used to examine whether orexins’ activity is related to somatic symptoms of opiate withdrawal and
alterations in HPA axis and extended amygdala in rats dependent on morphine. OXA mRNA was induced in the
hypothalamus during morphine withdrawal, which was accompanied by activation of OXA neurons in the LH. Importantly,
SB334867 attenuated the somatic symptoms of withdrawal, and reduced morphine withdrawal-induced c-Fos expression in
the nucleus accumbens (NAc) shell, bed nucleus of stria terminalis, central amygdala and hypothalamic paraventricular
nucleus, but did not modify the HPA axis activity. These results highlight a critical role of OXA signalling, via OX1R, in
activation of brain stress system to morphine withdrawal and suggest that all orexinergic subpopulations in the lateral
hypothalamic area contribute in this response.
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Introduction
Orexin-A (OXA) and Orexin-B (OXB) (also known as
hypocretin-1 and hypocretin-2, respectively) are neuropeptides
synthesized exclusively in hypothalamus that are involved in
several physiological processes [1,2]. Two G protein-coupled
receptors have been identified for the orexin system, orexin
receptor type 1 (OX1R) and orexin receptor type 2 (OX2R).
Whereas OX1R binds OXA with higher affinity (30 nM) than
OXB, OX2R binds both orexins with equal affinity [1]. Generally,
it is thought that OX1R is coupled to Gq, and OX2R is coupled to
Gq or Gi/Go, but signalling mechanisms are cell specific and has
not been systematically studied. Orexinergic neurons are localized
in the lateral hypothalamus (LH): the lateral region (LLH),
perifornical area (PFA), and dorsomedial hypothalamus (DMH)
[1,3,4], while their projections are widely distributed in many
brain areas [4]. Orexinergic neurons arising in the DMH and PFA
project to brainstem nuclei and involved in control of arousal and
modulation of stress responses [5]. Neurons from the LLH project
to brain areas broadly related to positive reinforcing effects of
drugs (ventral tegmental area, VTA, nucleus accumbens, NAc;
[4,5]). So, orexins have been lately related to reward and addiction
processes.
Several neurotransmitters/neuromodulators, including cortico-
tropin- releasing factor (CRF), ghrelin, neurotensin, vasopressin
and oxytocin excite OXA neurons. On the other hand,
noradrenaline (NA), dopamine (DA), serotonin, neuropeptide Y,
and leptin inhibit orexinergic cells [6]. CRF is widely distributed
throughout the brain and plays a major role in coordinating the
behavioral and autonomic responses to stress [7]. CRF is released
from two brain regions to participate in two separate (but
connected) stress systems. In the hypothalamo-pituitary-adrenal
(HPA) axis stress system, CRF neurons in the parvocellular region
of the hypothalamic paraventricular nucleus (PVN) regulate the
release of pituitary adrenocorticotropic hormone (ACTH) and
adrenal glucocorticoids. In the extrahypothalamic stress system,
CRF neurons in the central nuleus of amygdala (CeA) and in the
bed nucleus of the stria terminalis (BNST) excite noradrenergic
neurons in the locus coeruleus (LC) and the nucleus of the solitary
tract (NTS). Increased activity of this ascending noradrenergic
system results in activation of CeA, BNST and PVN neurons. The
activation of the CRF neurons of the PVN is also associated with
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36871increased activity in the NTS [8,9]. In addition, CRF has been
reported to contribute to the anxiogenic and adverse symptoms of
withdrawal from exposure to several drugs of abuse, including
cocaine and opiates [9,10].
Recent investigations revealed participation of the orexinergic
system in brain stress system [11]. The present study was designed
to evaluate changes in the orexinergic system during naloxone-
precipitated morphine withdrawal. We addressed the role of
orexinergic inputs in the development of somatic signs of the
opiate abstinence syndrome and the brain stress systems responses
to morphine withdrawal.
It has been reported that OXA activates PVN neurons [12] and
that intracerebroventricular (i.c.v.) OXA increases plasma levels of
glucocorticoids and ACTH [13]. However, it remains to be
determined whether OXA modulates the activity of the extra-
hypothalamic CRF neurons. Further aim of this work was to
confirm the orexin projections to the main nuclei of the brain
stress system, such as NAc shell, BNST, PVN, CeA, and NTS, and
to study the effect of pharmacological blockade of the orexinergic
system, by OX1R antagonist (SB334867) administration, on the
somatic symptoms produced during morphine withdrawal. In
addition, c-Fos expression in the brain stress system and
glucocorticoids release during morphine withdrawal were mea-
sured in morphine-dependent SB334867-treated rats.
Results
OX1R antagonist SB334867 attenuates somatic
expression of naloxone-precipitated morphine
withdrawal
Six days after the implantation of morphine or placebo pellets,
rats were challenged with naloxone (1 mg/kg s.c.) and immedi-
ately tested for the occurrence of somatic signs of opiate
withdrawal. The following somatic signs were significantly present
in morphine-treated groups (n=8) when compared with placebo-
treated groups (n=7): wet dog shakes (p,0.001), sniffing
(p,0.001), writhing (p,0.001), body tremor (p,0.001), ptosis
(p,0.001), diarrhea (p,0.001), piloerection (p,0.001), teeth
chattering (p,0.001), paw tremor (p,0.05), mastication
(p,0.001), and body weight loss (p,0.001; n=10). The analysis
of the global withdrawal score confirmed these differences between
morphine- and placebo-treated rats (p,0.001). The results for
two-way ANOVA analysis are shown in Table 1. When OX1R
receptors were blocked, comparisons between morphine (n=9)
groups showed that wet dog shakes (p,0.001), sniffing (p,0.001),
writhing (p,0.01), body tremor (p,0.001), ptosis (p,0.001),
diarrhea (p,0.001), piloerection (p,0.01), and mastication
(p,0.001) were significantly decreased in morphine-dependent
rats receiving SB334867 before naloxone (Table 1, Figure 1A–K).
The analysis of the global withdrawal score confirmed that
SB334867 significantly reduced somatic expression of withdrawal
in morphine-treated rats (p,0.001; Table 1, Figure 1L). Thus, the
blockade of OX1R overall decreased the expression of naloxone-
precipitated somatic signs of opiate withdrawal, reducing global
scores of morphine-dependent SB334867-treated rats. No changes
were seen in the placebo-treated group receiving SB334867 (n=6)
and the control group injected with vehicle.
Naloxone-precipitated morphine withdrawal induces
orexin gene expression
Next, we assessed if activation of orexinergic neurons in
response to chronic morphine treatment and precipitated with-
drawal results in induction of orexin gene expression. Time course
of changes in OXA mRNA levels was followed in the hypotha-
lamic samples by quantitative RT-PCR (Figure 2). When
compared to placebo implanted controls (n=6) no change in
mRNA levels was detected in response to chronic morphine (n=6)
or to naloxone in morphine-naı ¨ve animals (n=5). Two-way
ANOVA showed that there was a significant morphine pre-
treatment main effects (30 min: F(1,17)=16.38, p=0.0008;
60 min: F(1,18)=20.80, p=0.0002), a significant naloxone main
effect (30 min: F(1,17)=7.803, p=0.0125; 60 min:
F(1,18)=10.98, p=0.0039) and a significant interaction ‘‘mor-
phine pretreatment’’ X ‘‘SB treatment’’ (30 min: F(1,17)=14.80.
p=0.0013; 60 min: F(1,18)=19.03, p=0.0004). Neuman Keuls’
post hoc test showed that at 30 (n=4) and 60 (n=5) min after
naloxone injection there was a significant increase mRNA
expression compared with placebo groups receiving naloxone
(p,0.001; p,0.001, respectively) and with morphine-dependent
animals receiving saline instead naloxone (p,0.001; p,0.001,
respectively).
Chronic morphine treatment and naloxone-precipitated
morphine withdrawal do not modify the number of OXA
neurons in the LH
To evaluate if chronic morphine and naloxone-precipitated
morphine withdrawal differentially affects the number of OXA
neurons in the LH, the cell counts of OXA immunoreactive
profiles were taken in three sub-population of the LH: DMH, PFA
and LLH. The two-way ANOVA performed on the number of
OXA-positive neurons in placebo (n=5)- and chronic morphine-
treated rats (n=5), with or without naloxone injection, indicated
that there was not a significant morphine pretreatment main
effects, no significant naloxone main effect nor a significant
interaction [DMH: morphine pretreatment, F(1,16)=0.25;
p=0.6271; naloxone injection, F(1,16)=0.91; p=0.3556; in-
teraction, F(1,16)=0.14; p=0.7143. PFA: morphine pretreat-
ment, F(1,16)=0.00; p=0.9863; naloxone injection,
F(1,16)=0.32; p=0.5979; interaction, F(1,16)=1.28; p=0.2754.
LLH: morphine pretreatment, F(1,16)= 0.90; p=0.3569; nalox-
one injection, F(1,16)= 0.06; p=0.8174; interaction,
F(1,16)=0.67; p=0.4246]. As depicts in Figure 3F, chronic
morphine or naloxone injection did not significantly alter the
number of OXA neurons in the LH.
Naloxone-precipitated morphine withdrawal activates
OXA neurons
c-Fos protein, the product of c-fos immediate early gene, has
been used as a marker for neuronal activation. To reveal if OXA
neurons are activated during naloxone-precipitated morphine
withdrawal, c-Fos and OXA immunostaining was co-localized and
quantified in sections of the lateral hypothalamic area (Figure 4A–
D). Two-way ANOVA revealed main effect of morphine
treatment [DMH: F(1,18)=8.98; p=0.0077; PFA:
F(1,18)=13.74; p=0.0016; LLH: F(1,18)=28.20; p,0.0001],
naloxone injection [DMH: n.s.; PFA: F(1,18)=10.04; p=0.0053;
LLH: F(1,18)=26.82; p,0.0001], and interaction between pre-
treatment and acute treatment [DMH: F(1,18)=9.79; p=0.0058;
PFA: F(1,18)=14.70; p=0.0012; LLH: F(1,18)=27.10;
p,0.0001]. Post hoc analysis revealed that morphine withdrawal
(n=7) increased (p,0.001) the number of OXA-containing
neurons expressing c-Fos in all three subpopulation of the LH
compared with placebo controls receiving naloxone (n=5) and
morphine-treated rats injected with saline (n=5) instead of
naloxone (Figure 4E). Administration of the opioid antagonist to
control rats did not induce any modification, compared with
control groups receiving saline (n=5).
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morphine withdrawal-evoked activation of
extrahypothalamic and hypothalamic brain stress
systems
We assessed the influence of the OX1R antagonist SB334867
on c-Fos expression in the brain stress system (NAc shell, BNST
and CeA; Figure 5) as well as on the PVN and NTS-A2
noradrenergic cell group (Figure 6). Two-way ANOVA indicated
that there were significant effects of morphine pretreatment,
SB334867 administration and ‘‘morphine pretreatment’’ X ‘‘SB
treatment’’ interaction on c-Fos expression in the NAc shell
[morphine pretreatment: F(1,22)=59.45; p,0.0001; SB treat-
ment: F(1,22)=6.35; p=0.0195; interaction: F(1,22)=4.77;
p=0.0400], CeA [morphine pretreatment: F(1,20)=114.76;
p,0.0001; SB treatment: F(1,20)=9.17; p=0.0066; interaction:
F(1,20)=16.26; p=0.0007], and PVN [morphine pretreatment:
F(1,21)=53.84; p,0.0001; SB treatment: F(1,21)=5.35;
p=0.0310; interaction: F(1,21)=16.11; p=0.0006]. The two-
way ANOVA also indicated that there were significant effect of
morphine pretreatment and ‘‘pretreatment’’ X ‘‘SB treatment’’
interaction on c-Fos expression in the BNST [pretreatment:
F(1,21)=55.90; p,0.0001; Interaction: F(1,21)=12.41;
Figure 1. Attenuation of the severity of somatic signs of naloxone-precipitated morphine withdrawal up to 30 min after the
naloxone injection by SB-334867 pretreatment. The following variables were counting: (A) wet-dog shakes; (B) sniffing; (C) writhing; (D) body
tremor; (E) ptosis; (F) diarrhoea; (G) piloerection; (H) mastication; (I) teeth chattering; (J) paw tremor; (K) body weight loss. Somatic signs of withdrawal
were observed during 30 min immediately after naloxone injection (1 mg/kg s.c.) A global withdrawal score (L) was calculated for each animal as
described in Methods. Data are expressed as mean 6 SEM. *p,0.05; ***p,0.001, versus placebo + vehicle (veh) + naloxone (nx);
++p,0.01;
+++p,0.001 versus similar groups receiving vehicle instead of SB-334867.
doi:10.1371/journal.pone.0036871.g001
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NTS [F(1,19)=29.83; p,0.0001].
Post hoc analysis (Figure 5J) revealed that morphine withdrawal
increased (p,0.001) c-Fos expression in the extended amygdala:
NAc shell; (Figure 5B; n=6), BNST (Figure 5E; n=6) and CeA
(Figure 5H; n=7). We observed similar significant increase in c-
Fos expression in the PVN (p,0.001; n=7) and NTS (p,0.01;
n=5). We also observed that the main effect of SB334867
administration was to decrease c-Fos expression. This effect was
significant across extended amygdala areas (Figure 5C, F, I, J;
NAc, n=8; BNST, n=8) and the PVN (Figure 6B, C; n=8).
OXA fibers project to the extended amygdala, PVN and
NTS
Whereas OXA cell bodies are restricted to the LH, OXA nerve
fibers project widely into the extended amygdala (NAc shell,
BNST and CeA), PVN, and NTS, areas that are critically involved
in addiction and brain stress system (Figure 7). A double-label
immunohistochemical staining was carried out to investigate the
overlap between CRF, TH- and pro-DYN-immunopositive cells
and OXA containing fibers. Figure 7 shows close opposition of
OXA-immunoreactive fibers and CRF-, TH and pro-DYN-
immunoreactive pericarya. Distributed throughout the NTS-A2
catecholaminergic cell group, and intermingled with TH-contain-
ing cells numerous OXA-immunoreactive axons were found
(Figure 7A). In shell region of the NAc OXA containing
varicosities were observed in close apposition with pro-DYN-
containing neurons (Figure 7C). At more caudal level, in the
BNST, thin OXA-containing fibers have been revealed in overlap
with CRF-containig neurons (Figure 7B). OXA-immunoreactive
axons juxtaposed to CRF-containing cells were present in the CeA
(Figure 7E). OXA-immunoreactive axons densely innervated the
hypothalamic paraventricular nucleus and were found in in close
apposition to CRF neurons in the medial parvocellular sub-
division. (Figure 7D).
OX1R antagonism decreases CeA CRF activity during
naloxone-precipitated morphine withdrawal
We also tested the influence of the OX1R antagonist SB334867
on activation of CRF neurons (as assessed by double immunos-
taining with anti-c-Fos and anti-CRF antibodies) in the PVN,
BNST, and CeA (Figure 8). Two-way ANOVA for c-Fos
expression in CRF neurons in the PVN revealed a main effect
of morphine treatment [F(1,23)=123.63; p,0.0001] but no
significant effect either of SB334867 pretreatment or ‘‘pretreat-
ment’’ X ‘‘SB treatment’’ interaction. The two-way ANOVA for
c-Fos expression in CRF neurons in the BNST showed no
significant effect of morphine pretreatment, SB334867 adminis-
tration or ‘‘pretreatment’’ X ‘‘SB treatment’’ interaction. The two-
way ANOVA for c-Fos expression in CeA CRF neurons revealed
main effect of morphine pretreatment [F(1,21)=9.96; p=0.0048],
SB334867 administration [F(1,21)=12.92; p=0.0017] but no
interaction between morphine pretreatment and SB334867
treatment. Post hoc analysis revealed that morphine withdrawal
Table 1. SB334867 attenuates the somatic expression of naloxone-precipitated morphine withdrawal.
Two-Way ANOVA
Chronic treatment (morphine vs placebo) Pretreatment (SB334867 vs vehicle) Interaction
Signs F 1,27 p, F1,26 p, F1,26 p,
Wet dog shakes 61.39 0.0001 4.19 n.s 4.19 n.s
Paw tremor (P25) 10.62 0.0032 1.07 n.s 1.07 n.s
Sniffing 22.32 0.0001 15.94 0.0005 15.94 0.0005
Writhing 21.35 0.0001 4.20 n.s 4.20 n.s
Tremor 122.75 0.0001 16.47 0.0004 16.47 0.0004
Ptosis 101.57 0.0001 43.45 0.0001 43.45 0.0001
Mastication 70.96 0.0001 1.70 n.s 1.70 n.s
Teeth chatering 16.08 0.0005 1.10 n.s 1.10 n.s
Piloerection 120.27 0.0001 3.79 n.s 3.79 n.s
Diarrhea 70.86 0.0001 21.63 0.0001 21.63 0.0001
Weight loss (P31) 28.42 0.0001 0.18 n.s 0.18 n.s
Global score (P27) 124.27 0.0001 8.66 0.0066 8.66 0.0066
Two-way ANOVA with chronic treatment (morphine vs. placebo) and pretreatment before naloxone (SB334867 vs. vehicle) as between-subjects factors. When significant
interactions in pretreatment or between these two factors were observed, a subsequent post hoc test was applied.
doi:10.1371/journal.pone.0036871.t001
Figure 2. Morphine withdrawal induced OXA gene expression
in the hypothalamus. Rats were sacrificed at different time-points
(15, 30, 60 and 120 min) after saline or naloxone injection. Mean 6 SEM
RQ (relative quantification of the comparative CT experiments)
expression values were obtained by real-time qPCR measurement,
where the expression of OXA gene in morphine withdrawn rats is
expressed relative to the placebo implanted controls receiving
naloxone. ***p,0.001 versus placebo + naloxone;
+++p,0.001 versus
morphine + saline.
doi:10.1371/journal.pone.0036871.g002
Orexins, Brain Stress System, Morphine Withdrawal
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36871Figure 3. Chronic morphine and morphine withdrawal do not modify the number of OXA neurons in the DMH, PFA and LLH regions
of the lateral hypothalamus. Placebo and morphine-dependent groups were sacrificed 120 min after saline or naloxone administration. (A)
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expressing c-Fos in the PVN (n=8), which indicates an activation
of CRF neurons, compared with placebo controls receiving
naloxone (n=5). In these neurons, there was no effect of
SB334867 administration on c-Fos expression (Figure 8A–D, I;
n=9). In the CeA (Figure 8G, H, I), there was a significant
increase in c-Fos expression in CRF-positive neurons (p,0.01;
n=7). The SB334867 pretreatment significantly attenuated
(p,0.05; n=6) the increase in c-Fos expression in CRF CeA
neurons, which indicates that there is a greater OXA input to CeA
CRF neurons during morphine withdrawal.
OX1R blockade does not antagonize naloxone-
precipitated morphine withdrawal-induced HPA axis
activation
We measured plasma corticosterone concentrations (as HPA
axis activation marker) in blood samples obtained from morphine-
dependent or control rats 2 h after injection of naloxone. Two-
way ANOVA for corticosterone revealed significant effect of
chronic morphine treatment [F(1,25)=29.72; p,0.0001] and
significant effect of acute treatment [F(1,25)=9.64; p=0.0047].
As shown in Figure 9, plasma corticosterone levels increased
significantly (p,0.001) in vehicle pretreated, morphine withdrawn
rats. To evaluate if there is a link between OX1R activation and
HPA axis hyperactivity during morphine withdrawal, plasma
corticosterone concentrations were measured in animals made
dependent on morphine and pretreated with SB334867 before
naloxone administration. Corticosterone levels in SB334867 plus
naloxone-treated morphine-pelleted animals were significantly
(p,0.01; n=9) higher than those observed in the placebo group
also administered SB334867 plus saline (n=6). No significant
differences were seen between morphine-dependent rats receiving
vehicle before naloxone and those receiving SB334867. In
addition, placebo-pelleted rats receiving SB334867 showed
significant (p,0.05) higher plasma corticosterone concentrations
compared with its control receiving vehicle instead of SB334867
(n=6).
Discussion
This report provides evidence in rats of the critical involvement
of orexinergic system via OX1R in activation of brain stress system
during morphine withdrawal.
In agreement with previous data [14,15], present results show
an important role for OXA and OX1R pathways in the somatic
expression of opiate withdrawal as well as in molecular changes
within the brain stress systems induced by morphine withdrawal.
Naloxone administration to morphine dependent rats induced
robust withdrawal symptoms. Our results indicate that the
blockade of OX1R significantly decreased several of the somatic
signs of naloxone-precipitated morphine withdrawal as well as the
global score, suggesting that activation of OX1R pathways might
positively modulate the somatic expression of opiate withdrawal.
These data are in agreement with previous results showing that
administration of SB334867 directly into LC to rats attenuates
signs of morphine withdrawal [16]. In addition, mice lacking the
pre-propeptide encoding for orexins or pretreated with SB334867
display markedly reduced symptoms of opiate withdrawal [14,15].
In the present study we demonstrate that in rats, the involvement
of OXA in morphine withdrawal somatic symptoms is mediated,
at least in part, by OX1R.
Previous study on orexin-T-LacZ reporter mice indicated that
morphine withdrawal stimulates the transgene expression. Using
quantitative real time PCR measurement, here we provide a direct
evidence for activation of OXA gene expression in the rat
hypothalamus during morphine withdrawal. Furthermore, OXA
mRNA levels peak between 30–60 min after naloxone adminis-
tration. This timing of transcriptional activation is compatible with
CRE-mediated transcription as it has been shown in the
orexinergic neurons of morphine-withdrawn CRE-LacZ reporter
mice [14]. Indeed, naloxone-precipitated morphine withdrawal
results in activation of orexin neurons in the lateral hypothalamus
as revealed by immunocytochemical detection of c-Fos protein. In
contrast to the situation seen in morphine withdrawn mice, cell in
all the three functionally distinct subpopulation of hypothalamic
orexinergic neurons became c-Fos positive upon morphine
withdrawal in rats.
Heterogeneity in orexin neurons has been described in previous
animal studies [17]: orexinergic neurons located in the DMH and
PFA have been suggested to control arousal and modulate stress
responses, whereas neurons in the LLH project to areas related to
positive reinforcing effects of drugs. We have confirmed activation
of orexin neurons in the DMH and PFA [14,15], however, for the
first time, demonstrate that morphine withdrawal induces c-Fos
expression in orexinergic neurons in the LLH subdivision. This
result suggests that LLH may also be a critical region contributing
to morphine withdrawal response in rats. The disparities between
our recent data and previous studies might originate from species
difference (rat vs mouse) or from methodological differences, since
escalating morphine doses in mice were used by Sharf et al. (2008)
[15].
Interestingly, present work also shows hyperactivation of the
brain stress system during morphine withdrawal that was
attenuated by SB334867. Given that the PVN receives orexinergic
inputs arising from both the PFA and the LLH subdivisions of the
LH [18], our data might suggest the involvement of OXA neurons
arising not only from the DMH and PFA, but also from the LLH,
in the activation of the brain stress system during opiate
withdrawal.
Both the HPA axis and the extended amygdala are dysregulated
by chronic administration of drugs of abuse [10,19,20]. Further-
more, acute drug withdrawal may also increase the activity of
noradrenergic pathways innervating the CeA and the PVN [20–
22]. All these processes are involved, at least in part, in the
negative motivational states during drug withdrawal. Presents
results show an enhancement of c-Fos expression during morphine
withdrawal in the main nuclei of the extended amygdala, and in
the PVN, the apex of the HPA axis. The NTS-A2 cell group, the
main noradrenergic cell group innervating the brain stress system
[8], is also activated after naloxone-precipitated opiate withdrawal.
Present data shows that SB334867 administration attenuates this
activation of the extended amygdala and the PVN, suggesting that
the orexinergic system, via OX1R, might play a main role in
regulating the activation of the brain stress systems during acute
opiate withdrawal. The presence of orexinergic fibers as well as
OX1R and/or OX2R within all these nuclei showed in the
present work and others [4] supports this hypothesis [23]. The
present study shows that the OXA system provides anatomical
Schematic anatomic representation of LH subdivisions adapted from Paxinos and Watson stereotaxic atlas [42]. (B–E, E9) Representative photographs
illustrating regional orexin A cell expression in the LH. (F) Mean 6 SEM in the three regions of the LH. 3V, third ventricle; f, fornix. Scale bars, 200 mm
(B–E) and 20 mm( E 9).
doi:10.1371/journal.pone.0036871.g003
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36871Figure 4. Naloxone-induced morphine withdrawal results in activation of orexin A cells in the DMH, PFA and in the LLH. (A–D)
Representative photographs showing double-label immunohistochemistry for c-Fos and OXA in the LH. (D9) High magnification image showing c-
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the PVN and the NTS. Light microscopic double immunocyto-
chemical analysis revealed close apposition between OXA fibers
and CRF-, pro-DYN- and TH-expressing in the PVN, CeA, NAc
and NTS respectively. These findings provide an anatomical basis
for potential modulation of CRF, noradrenergic and DYN
neurons by OXA.
NAc shell has been related to the expression of morphine
withdrawal somatic symptoms [15], together with the CeA and
BNST [24,25]. Supporting this hypothesis, present results showed
that attenuation of somatic signs during opiate withdrawal was
accompanied by a decrease of c-Fos expression in these sites.
All major drugs of abuse stimulate the HPA axis during acute
withdrawal [10,19]. The PVN receives OXA and OXB projec-
tions, both of them originating in the PFA and LLH, although
OXA immunoreactive fibers are found in higher densities than
those of OXB. Regarding OX receptors, OX2R mRNA is
predominant in the PVN [18]. However, conflicting findings have
been published concerning the activity of the orexinergic system
on the HPA axis [18,26]. The results of the present study show
that morphine withdrawal induced an increase in corticosterone
release, which was not blocked by SB334867 administration.
When we examined the action of SB334867 on the activity of the
CRF neurons in the PVN during morphine withdrawal, we found
that both the morphine-dependent rats injected with SB334867 or
with vehicle showed similar responses to naloxone injection. Since
there was an attenuation of c-Fos expression in the PVN after
SB334867 administration in morphine-withdrawn rats, and our
results show that this decrease does not occur in the CRF neurons,
it could be suggested that the activity of other PVN neurons, such
as AVP-containing cells (which also participates in ACTH and
then in glucocorticoids release), is inhibited by the OX1R
antagonist. Given that OX2R mRNA is predominantly expressed
in the PVN [23], and that the administration of OX2R antagonist
to rats inhibits ACTH release induced by OXA or stress [18], it
might be postulated that the action of OXA at this level would be
mediated mainly by the OX2R. Thus, it seems logical that the
responsiveness of the PVN CRF neurons and the HPA axis to
morphine withdrawal did not change after blocking OX1R.
However, SB334867 administration induced a slight activation of
CRF neurons in the PVN and glucocorticoids release in control
rats. Since OXA binds to OX1R and OX2R with similar affinity
[1], and we have blocked OX1R, OXA might bind exclusively to
OX2R. Thus, OX2R stimulation in the PVN would result in
CRF-containing cells activation and in glucocorticoids release.
Furthermore, it is well established that orexins exert an influence
on the regulation of the hypothalamus-pituitary-adrenal axis,
acting both on its central peripheral branch [27].
Numerous studies have supported the importance of the
brainstem noradrenergic afferents in regulating the brain stress
system during opiate withdrawal [8,22,25,28]. Since SB334867
administration did not block the activation of the NTS, our data
do not support a role of the OX1R pathways in regulating the
activity of the noradrenergic A2 cell group.
Extended amygdala nuclei and their neurotransmitter systems
have been related with the positive reinforcing effects of drugs, as
well as with the negative reinforcing effects of drugs withdrawal
[10]. It has been previously reported that OXA has an excitatory
action on the CeA [29], and that this activation occurs in CRF-
containing neurons [30]. Accordingly, our results show an increase
in c-Fos expression in CRF-positive neurons in the CeA during
naloxone-induced morphine withdrawal, which was blocked by
SB334867. These data indicate the involvement of the orexinergic
system in modulating the response to opiate withdrawal syndrome
in the CeA via OX1R.
The BNST neurons are innervated by orexin-immunoreactive
fibers originating in the LH [4,5], and display moderate levels of
OX1R expression. [23]. In addition, BNST receive noradrenergic
inputs originating in the NTS [25]. Present data show that BNST
CRF neurons were not activated after naloxone administration to
morphine dependent rats, which is in agreement with previous
data showing no increase in c-Fos expression in BNST CRF
neurons in morphine-withdrawn rats [31]. Just like in the PVN,
SB334867 administration did not alter the response of BNST CRF
neurons to morphine withdrawal. Should be taken into account is
that these two nuclei receive important noradrenergic inputs from
the NTS [28,32], whose activation in morphine-withdrawn rats is
not attenuated by the OX1R antagonist.
In summary, this study provides evidences of activation of
orexinergic in the three subdivisions of the LH during naloxone-
induced morphine withdrawal that is accompanied with increased
OXA mRNA transcription and increased OXA input to brain
stress system. Furthermore, present data reveal a critical in-
volvement of the orexinergic system in the physical symptoms of
opiate abstinence syndrome, supporting a therapeutic potential of
OX1R antagonists in addictive disorders, as has been proposed
[15,33]. Present findings highlight the pivotal role of orexins in the
activation of the hypothalamic and extrahypothalamic brain stress
systems during opiate withdrawal in rats.
Methods
Animals
Male Wistar rats (220–240 g, at the beginning of the
experiment; Harlan, Barcelona, Spain) were housed 2–3 per cage,
in a room with controlled temperature (2262uC) and humidity
(50610%), with free access to water and food (Harlan Teklad
standard rodent chow; Harlan Interfauna Ibe ´rica, Barcelona,
Spain). Animals were adapted to standard 12-h light-dark cycle
(lights on: 08:00–20:00 h) for 7 days before the beginning of the
experiments. For the behaviour study rats were housed in-
dividually in the same room. Allsurgical and experimental
procedures were performed in accordance with the European
Communities Council Directive of 24 November 1986 (86/609/
EEC), and approved by the local Committees for animal research
(REGA ES300305440012, Murcia and Institutional Animal Care
and Use Committee of the Institute of Experimental Medicine,
Budapest). The study was approved by the University of Murcia
bioethics committee (RD 1201/2005) and Ministerio de Ciencia y
Tecnologı ´a (SAF2009-07178), Spain.
Drug treatment and experimental procedure
Rats were made dependent on morphine by subcutaneous (sc)
implantation of two 75 mg slow-release morphine pellets (provided
by the Ministerio de Sanidad, Madrid, Espan ˜a) for 6 days under
light ether anaesthesia. Control rats received placebo pellets
containing the excipient without morphine. This procedure has
been shown to produce constant plasma morphine concentration
Fos-positive (black)/OXA-positive (brown) neurons. 3V, third ventricle; f, fornix. Scale bars, 200 mm (A–D) and 50 mm( D 9). Arrows indicate c-Fos in
OXA-positive neurons. (E) Regional expression of c-Fos in OXA positive cells. Bars represent the mean 6 SEM.
+++p,0.001 versus morphine + saline;
***p,0.001 versus placebo + naloxone.
doi:10.1371/journal.pone.0036871.g004
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e36871Figure 5. Naloxone-induced morphine withdrawal results in activation of extended amygdala. SB-334867 attenuated c-Fos
expression in the NAc, BNST and CeA in morphine-withdrawn rats. Rats were pretreated with the selective OX1R antagonist SB334867
20 min prior naloxone injection and were sacrificaed 120 min after naloxone administration. (A, D, G) Schematic anatomic representation of NAc
shell, BNST and CeA adapted from Paxinos and Watson atlas (2007). Labeled areas delineate regions where c-Fos expression was examined. (B I)
Representative photographs of c-Fos expression in the NAc, BNST (oval) and CeA in animals pretreated with morphine-vehicle-naloxone (B, E, H) or
with morphine-SB-334867-naloxone (C, F, I). LV, lateral ventricle; ac, anterior comissure; BLA, basolateral amygdala. Scale bar, 200 mm. (J)
Quantification of neurons expressing c-Fos in the NAc shell, BNST (oval) and CeA. Bars represent mean 6 SEM. ***p,0.001 versus placebo + vehicle
(veh) + naloxone (nx);
++p,0.01;
+++p,0.001 versus placebo + SB-334867+ naloxone;
##p,0.01,
###p,0.001 versus morphine + vehicle + naloxone.
doi:10.1371/journal.pone.0036871.g005
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PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e36871starting a few hours after implantation of the pellets and morphine
dependence as revealed by expression of full withdrawal syndrome
after acute injection of opioid antagonists [34]. Dependence on
morphine (as measured by withdrawal response) is achieved 24 h
after implantation of pellets and remained constant for 15 days
[35]. Six days after the implantation of morphine or placebo
pellets, precipitated withdrawal was induced by s.c. injection of
naloxone (1 mg/kg; in a volume of 1 mL/kg body weight).
The experimental conditions investigated for the different assays
were: orexin gene expression: (i) placebo + saline (n=6), (ii)
placebo + naloxone (n=5), (iii) morphine + saline (n=6), (iv)
morphine + naloxone 15 min (n=4), (v) morphine + naloxone
30 min (n=4), (vi) morphine + naloxone 60 min (n=5), (vii)
morphine + naloxone 120 min (n=4); activation of the orex-
inergic neurons of the LH and the number of orexinergic neurons
during morphine dependence and withdrawal: (i) placebo + saline
120 min (n=5), (ii) placebo + naloxone 120 min (n=5), (iii)
morphine + saline 120 min (n=5), (iv) morphine + naloxone
120 min (n=7); opiate withdrawal-induced physical signs of
dependence, c-Fos expression in the brain stress system, activation
of the CRF neurons of the BNST, PVN and CeA and
corticosterone release: (i) placebo + vehicle + naloxone 120 min
(n=6), (ii) placebo + SB334867 + naloxone 120 min (n=5), (iii)
morphine + vehicle + naloxone 120 min (n=8), (iv) morphine +
SB334867 + naloxone 120 min (n=9).
Measurement of the withdrawal syndrome
Experiments were carried out in a quiet room. The observer
was unaware of the drug combination used. Rats were individually
placed into transparent plastic cages 15 min before the naloxone
injection and observed continuously for the occurrence of somatic
signs of opiate withdrawal up to 30 min after the naloxone
injection, at which time most of the acute behavioral effects
manifest [36]. Subsequently, previously identified behavioral
characteristics of the rat opiate withdrawal [37] were evaluated
including: wet-dog shakes, jumping, paw tremor, teeth chattering,
mastication, ptosis, piloerection, sniffing, writhing, tremor and
diarrhoea. The number of wet-dog shakes, jumping, sniffing, and
paw tremor was counted as the number of events occurring during
the total test time period (graded signs). Teeth chattering, body
tremor, mastication, ptosis, piloerection and diarrhoea were scored
1 for appearance or 0 for non-appearance within each 5 min time.
To obtain a comprehensive index of the severity of somatic opioid
withdrawal including all the signs examined, a global withdrawal
score was calculated for each animal by giving each individual sign
a relative weight as previously reported [38]: jumping x 0,8; wet
dog shakes x 1; paw tremor x 0,35; sniffing x 0,5; writhing x 0,5;
ptosis x 1,5; teeth chattering x 1,5; body tremor x 1,5; diarrhoea x
1,5; mastication x 1,5 and piloerection x 1,5.
Body weight loss was determined as the difference between the
weight determined immediately before naloxone injection and
a second determination made 2 h later. The weight gain of the rats
was checked during treatment to ensure that the morphine was
liberated correctly from the pellets because it is known that chronic
morphine treatment induces a decrease in body weight gain due to
lower caloric intake [20,39].
In order to investigate the effect of the OX1R blockade on the
physical symptoms of morphine withdrawal, rats were pretreated
with the selective OX1R antagonist SB334867 [40], at the dose of
20 mg/kg i.p., 20 min prior saline or naloxone injection. This
dose of SB334867 is consistent with other recent studies [15,41].
Vehicle was delivered at the same volume as the SB334867
solution. The somatic signs of opiate withdrawal were evaluated
up to 30 min after naloxone injection. The following parameters
were determined two hours after saline or naloxone administra-
Figure 6. SB334867 attenuated naloxone-induced morphine withdrawal induction of c-Fos expression in the PVN but not in the
NTS. (A, D) Schematic anatomic representation of the PVN and NTS adapted from Paxinos and Watson atlas (2007). Labelled areas delineate regions
where c-Fos expression was examined. (B–F) Representative photographs of c-Fos expression in the PVN and NTS in animals pretreated with
morphine-vehicle-naloxone (B, E) or with morphine-SB334867-naloxone (C, F). Animals were sacrificed 120 min after naloxone administration. 3V,
third ventricle; AP, area postrema. Scale bar: 100 mm. (G) Quantification of neurons expressing c-Fos in the PVN (parvocellular subdivision) and in the
NTS-A2 catecholaminergic cell group. Bars represent mean 6 SEM. **p,0.01 ***p,0.001 versus placebo + vehicle (veh) + naloxone (nx);
+p,0.05;
++p,0.01 versus placebo + SB-334867+ naloxone;
###p,0.001 versus morphine + vehicle + naloxone.
doi:10.1371/journal.pone.0036871.g006
Figure 7. Immunohistochemical localization of orexin A nerve
fibers in the NTS, BNST, NAc, PVN and CeA in placebo-
implanted control rats. Representative photographs showing
double-label immunohistochemistry for TH and OXA (NTS, A), CRF
and OXA (BNST, B; PVN, D; and CeA, E) and pro-DYN and OXA (NAc, C).
Scale bar, 50 mm. Images depict the orexin A innervations (blue-black)
of the CRF, pro-DYN and TH neurons (brown) in the extended
amygdala, NTS and PVN. Higher magnification images of the boxes
areas depicted in each photomicrograph show examples of the areas
where OXA axons are opposed to the somata of CRF, TH and pro-DYN
cells. Abbreviations: NTS, nucleus of the solitary tract; BNST, bed
nucleus of the stria terminalis; NAc, nucleus accumbens; PVN,
hypothalamic paraventricular nucleus; CeA, central amygdala; cc, canal
central; 3V, third ventricle.
doi:10.1371/journal.pone.0036871.g007
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levels.
Primer design
Primers used for the comparative CT (threshold cycle)
experiments were designed by the Primer Express 3.0 program.
Primer sequences were the following:
Orexin-A:
Forward: TCCTTCAGGCCAACGGTAAC
Reverse: GGCAGGGATATGGCTCTAGCT
GAPDH:
Forward: ACAGCCGCATCTTCTTGTGC
Reverse: GCCTCACCCCATTTGATGTT
Dissection of whole hypothalamic samples
After decapitation at different time-points (15, 30, 60 and
120 min), the brain was rapidly removed from the skull and placed
to an RNase free rubber surface and the cerebellum was removed.
The boundaries of the hypothalamic blocks were at the optic
chiasm in rostral- at the mammillary bodies in caudal- and at the
hypothalamic sulcus in the lateral directions. The samples were
immediately frozen on dry ice and stored at 270uC until assay.
Quantitative real-time PCR
Total RNA was isolated from hypothalamic samples with
QIAGEN RNeasy MiniKit (Qiagen, Valencia, CA, USA)
according the manufacturer’s instruction. To eliminate genomic
DNA contamination DNase I treatment was used (100 ml Rnase
free DNase I (1 uDNase I, Fermentas) solution was added). Sample
quality control and the quantitative analysis were carried out by
NanoDrop (Thermo Scientific). Amplification was not detected in
the RT-minus controls. cDNA synthesis was performed with the
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA). The designed primers
(Invitrogen) were used in the real-time PCR reaction with Power
SYBR Green PCR master mix (Applied Biosystems, Foster City,
CA, USA) on ABI StepOne instrument. The gene expression was
analyzed by ABI StepOne2.0 program. The amplicon was tested
by Melt Curve Analysis on ABI StepOne instrument. Experiments
were normalized to GAPDH expression.
Perfusion and Immunohistochemical detection of OXA
and c-Fos
Two hours after naloxone or saline injections, rats were deeply
anesthetized with pentobarbital (100 mg/kg ip) and quickly
perfused through the ascending aorta with saline followed by
ice-cold fixative (paraformaldehyde 4%). Brains were post-fixed in
the fixative for 3 h and then placed in PBS containing 30% sucrose
overnight. Series of 30 mm frontal sections were cut on freezing
microtome, collected in cryoprotectant and stored at 220u C until
processing. After blocking with H2O2 and normal goat serum
(Sigma, St Louis, MO, USA) for c-Fos or normal rabbit serum for
OXA immunostaining, tissue sections were incubated in the
following primary antibodies: rabbit anti-c-Fos (1:10000, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) or goat anti-orexin-A
(1:2000, Santa Cruz). This was followed by application of
a biotinylated anti-rabbit or anti-goat IgG (Vector Laboratories,
Burlingame, CA, USA), and then with the avidin–biotin complex.
Visualization of the antigen–antibody reaction sites was performed
using 3, 39-diaminobenzidine (DAB, Sigma) nickel intensification
for c-Fos or DAB chromogen only for OXA. Sections were
mounted onto chrome-alumn gelatine coated slides, dehydrated
through graded alcohols, cleared in xylene and cover slipped with
dibutylphtalate (DPX).
Double-labelling immunohistochemistry of c-Fos-
immunoreactive nuclei and OXA-positive neurons or
CRF-positive neurons
For double-labelling, tissue sections from each rat in each
treatment group were processed for c-Fos immunoreactivity using
DAB nickel intensification and then OXA or CRF were revealed
using DAB chromogen only. Briefly, c-Fos immunostaining was
performed as described above. Following the c-Fos staining,
sections were rinsed in PBS, treated with bovine albumin serum or
goat serum and then incubated with the rabbit polyclonal anti-
OXA antibody or the rabbit policlonal anti-CRF antibody
(1:1000, a generous gift from Wylie Vale, The Salk Institute, La
Jolla, CA, USA). The same immunohistochemistry procedures
described above were followed. The OXA- or CRF-antibody-
peroxidase complex was developed in DAB. The sections were
mounted onto chrome-alumn gelatine coated slides and cover-
slipped.
Quantification of c-Fos immunoreactivity
Images were captured by means of DM4000B Leica microscope
(Leica, Madrid, Spain) equipped with a video camera (DFC290;
Leica). The distribution of c-Fos-positive cell nuclei was plotted
using a computer assisted image analysis system (QWIN; Leica,
Madrid, Spain). The boundaries of the NTS, the BNST, the CeA,
the shell of the NAc and the PVN were outlined and the number
of immune-positive profiles was recorded after thresholding the
images to a common level. The number of c-Fos nuclear profiles
Figure 8. OX1R antagonist SB334867 attenuates activation of CRF-containing neurons in the CeA but not in either the PVN or the
BNST. Microscopy showing double-label immunohistochemistry for c-Fos and CRF in the PVN (A–D), BNST (E, F) and CeA (G, H). (a–d): higher
magnification from (A–D). Scale bars, 100 mm (A–H); 50 mm (a–d). (I): mean 6 SEM. **p,0.01, ***p,0.001 versus placebo + vehicle + naloxone;
+++p,0.001 versus placebo + SB334867 + naloxone;
#p,0.05 versus morphine + vehicle + naloxone.
doi:10.1371/journal.pone.0036871.g008
Figure 9. Effects of OX1R antagonism on the morphine
withdrawal-induced increase in plasma corticosterone levels.
SB334867 did not attenuate the plasma corticosterone response to
naloxone-induced morphine withdrawal. Data represent the mean 6
SEM of corticosterone concentration 120 min after naloxone (nx)
injection to placebo- or morphine-treated rats receiving vehicle (veh)
or SB334867 (SB) 20 min before naloxone administration. Mean 6 SEM.
+p,0.05,
+++p,0.001 versus placebo + vehicle + naloxone **p,0.01
versus morphine + vehicle + naloxone.
doi:10.1371/journal.pone.0036871.g009
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in complete series of sections and estimates were corrected for
double-counting errors. To avoid observer bias, all sections were
quantified by a blinded investigator. Total counts for different
brain regions are expressed as mean 6 SEM.
Quantification of OXA-positive cells and c-Fos/OXA or c-
Fos/CRF double stained profiles
Images were captured by means of DM4000B Leica microscope
(Leica) equipped with a video camera (DFC290; Leica). The LH
was further subdivided into its three sub-populations: DMH, PFA
and LLH of the LH, and we measured the number of OXA
neurons in the three subpopulations. After labelling the area of
interest by a computer assisted image analysis system (QWIN;
Leica, Madrid, Spain) using identical rectangular frame (195 mm
side) first, single labelled OXA neurons were manually counted (X
20 magnification) in LH. Then, c-Fos/OXA and double stained
neurons were identified as profiles with blue/dark nuclear staining
in addition to brown cytoplasmic deposits. Four to six sections
from each rat were counted bilaterally at distinct rostro-caudal
levels of the LH and averaged to obtain a single value for each rat.
c-Fos-positive CRF (PVN, BNST, and CeA) double-stained
neurons were counted in the same way. All the counting was
made by a single researcher, who was blinded to all treatment
information.
Double-labelling immunohistochemistry of OXA fibers
and DYN- TH- or CRF-positive neurons
For double-labelling, tissue sections from each placebo-treated
rats were processed for OXA fibers immunoreactivity using DAB
nickel intensification and then pro-dynorphin (DYN), CRF or TH
were revealed using DAB chromogen only. Briefly, OXA fibers
immunostaining was performed as described above. Following the
OXA fibers staining, sections were rinsed in PBS, treated with 3%
bovine serum albumin and then incubated with the guinea-pig
anti-DYN antibody (1:2000, Neuromics, Edina, MN, USA), rabbit
anti-CRF antibody or anti-TH antibody (1:6000, Chemicon,
Temecula, CA). The same immunohistochemistry procedures
described above were followed. The DYN- and CRF- and TH-
antibody–peroxidase complex was developed in DAB. The
sections were mounted onto chrome-alumn gelatine coated slides
and coverslipped.
Radioimmunoassay
Two hours after saline or naloxone injection, rats were
decapitated (between 1100 and 1200 h to avoid circadian
variations in plasma levels of the hormones). Trunk blood was
collected, plasma was separated and levels of corticosterone were
measured by commercially available kits for rats (125I-corticoste-
rone RIA; MP Biomedicals, Orangeburg, NY). The sensitivity of
the assay was 7.7 ng/mL.
Materials
Pellets of morphine (75 mg morphine base/pellet; Alcaliber
Labs., Madrid, Spain) or lactose (placebo) were prepared by the
Department of Pharmacy and Pharmaceutics Technology (School
of Pharmacy, Granada, Spain); naloxone HCl was purchased from
Sigma, dissolved in sterile 0.9% NaCl (saline) and administered in
volumes of 0.1 ml/100 g body weight. DMSO was purchased
from Sigma. SB334867 (1-(2-methylbenzoxazol-6-yl)-3-
[1,5]naphthyridin-4-yl urea hydrochloride; Tocris, Bristol, UK)
was suspended in 2% DMSO and 10% 2-hydroxypropyl-b-
cyclodextrin (Sigma, St. Louis, MO) in sterile water; and was given
in a volume of 5 mL/kg (i.p.). Drugs were prepared fresh every
day.
Statistical analysis
Data are presented as mean 6 S.E.M. Data were analysed using
two-way or one-way (when required) analysis of variance
(ANOVA) followed by a post hoc Newman–Keuls test. Differences
with a P-value ,0.05 were considered significant.
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